Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes

• Material Type: 博士論文
• Title: Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
• Author/Editor: Abe, Takahiro
• Author Heading: Abe, Takahiro
• Publication Date: 2021-09-21
• Publication Date (W3CDTF): 2021-09-21
• Alternative Title: DPP-4阻害薬アナグリプチンは日本人2型糖尿病において血糖低下作用に関連し肝インスリンクリアランスを変化させる
• Degree grantor/type: 新潟大学
• Date Granted: 2021-09-21
• Date Granted (W3CDTF): 2021-09-21
• Dissertation Number: 甲第4936号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第4936号
• Text Language Code: eng
• Alias of Author: 阿部, 孝洋
• Subject Heading: Dipeptidyl peptidase-4 inhibitor; Hepatic insulin clearance; Meal tolerance test
• Target Audience: 一般
• Note (General): Aims/Introduction: This study investigated the impact of the dipeptidyl peptidase-4 inhibitor, anagliptin, on hepatic insulin clearance (HIC) in Japanese type 2 diabetes patients and explored its relationship to glycemic status. Materials and Methods: Data on 765 participants in anagliptin phase 2 and 3 studies were analyzed. Adjusted changes in variables during 12 weeks of anagliptin therapy were compared with a placebo. HIC was calculated as the ratio, C-peptide area under the curve 0–120 min to insulin area under the curve 0–120 min, after a meal tolerance test. To explore the effects of baseline HIC levels on variables, participants receiving anagliptin were divided according to quartiles of baseline HIC. Furthermore, multivariate analysis investigated the association between baseline HIC levels and glycemic status. Results: Anagliptin significantly reduced glycosylated hemoglobin levels (P < 0.001 vs placebo) and HIC levels (P < 0.01). Longer duration of diabetes, lower body mass index, higher glycosylated hemoglobin and lower insulin secretion capacity were observed with increases in baseline HIC levels. Improvements in glycosylated hemoglobin, glycoalbumin and 1,5-anhydroglucitol levels were greater in the relatively higher HIC group (baseline HIC levels ≥median) than in the lower HIC group (<median). Conclusions: Anagliptin affected HIC levels according to HIC baseline levels. Higher baseline HIC values might result in improved hyperglycemia through reduced HIC.; Journal of diabetes investigation. 2021, 12(10), 1805-1815.; 新大院博(医)第1026号
• Persistent ID (NDL): info:ndljp/pid/12297121; https://dl.ndl.go.jp/pid/12297121
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2022-06-05T18:01:14+09:00
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10191/0002000468; https://niigata-u.repo.nii.ac.jp/records/2000468
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp